LAMEA Sickle Cell Disease Treatment Market Size, Share & Industry Trends Analysis Report By Treatment (Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant), By End-Use (Hospitals, Specialty Clinics), By Country and Growth Forecast, 2023 - 2030

The Latin America, Middle East and Africa Sickle Cell Disease Treatment Market should witness market growth of 31.7% CAGR during the forecast period (2023-2030).

The market has been growing due to developments in treating anemia. Advancements have significantly influenced the market development for treating sickle cell disease in medicine and healthcare. Therefore, it is crucial to maintain the quantity and quality of hemoglobin in the blood. Recently, there has been an explosive increase in demand for sickle cell disease treatment.

The market has been developing along with the need to address disorders involving blood plasma. Sickle cell disease must be treated because hemoglobin deficiency can contribute to multiple bodily disorders. For patients with low hemoglobin levels, medical professionals advise prompt treatment methods. In the coming years, it is anticipated that this aspect will cause the market to increase more quickly. The market's expansion is also expected to be fuelled by rising per-capita healthcare costs and increased financing for logistical services.

Sickle cell disease is widespread in much of sub-Saharan Africa and affects a sizable percentage of births in several regions of the continent. The most prevalent form of SCD is SS disease, which occurs by homozygosity for the β-globin S gene mutation. Thus, because of the increasing number of screening and testing being conducted in the region, a significant proportion of the population is now aware about the impact of SCD. Such factors are aiding in the increasing demand for SCD treatment in the region.

The Brazil market dominated the LAMEA Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $120.2 Million by 2030. The Argentina market is showcasing a CAGR of 32.4% during (2023-2030). Additionally, The UAE market would register a CAGR of 31.4% during (2023-2030).

Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).

Scope of the Study

By Treatment

• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

By End-Use

• Hospitals
• Specialty Clinics
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Novartis AG
• Pfizer Inc.
• bluebird bio, Inc.
• CSL Limited
• Emmaus Life Sciences, Inc.
• Bristol Myers Squibb Company
• CRISPR Therapeutics AG
• Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
• Novo Nordisk A/S
• Medunik USA (Duchesnay Inc.)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free